2,092 reports of this reaction
1.2% of all VARENICLINE TARTRATE reports
#20 most reported adverse reaction
AGITATION is the #20 most commonly reported adverse reaction for VARENICLINE TARTRATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 2,092 FDA adverse event reports linking VARENICLINE TARTRATE to AGITATION. This represents approximately 1.2% of all 167,559 adverse event reports for this drug.
VARENICLINE TARTRATE has an overall safety score of 85 out of 100. Patients taking VARENICLINE TARTRATE who experience agitation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGITATION is a less commonly reported adverse event for VARENICLINE TARTRATE, but still significant enough to appear in the safety profile.
In addition to agitation, the following adverse reactions have been reported for VARENICLINE TARTRATE:
The following drugs have also been linked to agitation in FDA adverse event reports:
AGITATION has been reported as an adverse event in 2,092 FDA reports for VARENICLINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGITATION accounts for approximately 1.2% of all adverse event reports for VARENICLINE TARTRATE, making it a notable side effect.
If you experience agitation while taking VARENICLINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.